

JUN -7 2000

K000702  
p.1/2

**510(k) Premarket Notification**  
**Combilines™ Hemodialysis Blood Tubing Set**  
**Transducer Protector**

---

**510 (k) Summary**

**Submitter Name:** Fresenius Medical Care North America  
Two Ledgemont Center  
95 Hayden Avenue  
Lexington, MA 02420

**Contact Name:** Arthur E. Eilinsfeld  
Director, Fresenius Regulatory Affairs  
Telephone: 781-402-9068  
Fax: 781-402-9082

**Date of Summary:** February 25, 2000

**Trade Name:** Combilines™ Hemodialysis Blood Tubing Set  
Transducer Protectors

**Common Name:** Transducer protectors

**Classification Name:** Hemodialysis System and Accessories

**Substantial Equivalence Claim:** Substantial equivalence for the design and construction of the Borla TP as a kit ALTERNATE VENDED COMPONENT, is claimed to the Haemotronic TP [510(k) number K900841, May 15, 1990] predicate device. For the substantially equivalence of the VIRAL RETENTIVE claim for both the proposed Borla TP and the current Haemotronic TP kit components, the Medisystems Transducer Protectors [510(k) number K983076, November 25, 1998] is the predicate device.

**Device Description:** Combilines™ Transducer Protectors are designed to be used as protective devices for pressure monitors as well as to help maintain the sterility of the blood tubing fluid pathway. The 0.2µm hydrophobic membrane helps prevent cross-contamination by viruses, bacteria and particulate matter while preventing the flow of fluids to the hemodialysis machine pressure monitor.

**Statement of Intended Use:** Combilines™ Transducer Protectors are single use, disposable, prescription devices intended for use as protective devices for pressure monitors and to help protect the sterility of the fluid pathway. This is identical to the intended use of the legally marketed predicate device.

**Fresenius Medical Care North America**

Corporate Headquarters: Two Ledgemont Center 95 Hayden Avenue Lexington, MA 02420 (781) 402-9000

K000702  
p. 2/2

**510(k) Premarket Notification  
Combilines™ Hemodialysis Blood Tubing Set  
Transducer Protector**


---

**510 (k) Summary (continued)**

**Discussion of Technological Characteristics:** The technical characteristics of the device consist of a filter housing that contains a 0.2 µm hydrophobic membrane. The combination of the pore size and hydrophobic nature of the membrane prevents the flow of fluids, viruses, bacteria, and particulate matter into the pressure monitor at pressures lower than the rated pressure of the device.

**Safety and Effectiveness:** To assure that the device is safe and effective, all finished products are tested and must meet all required release specifications before distribution. The testing required for release includes sterility, functional testing\* visual inspection, pyrogenicity\*, and dimensional inspection.

\* Vendor certified

  
\_\_\_\_\_  
Arthur Eilinsfeld  
Director, Fresenius Regulatory Affairs

2/29/00  
\_\_\_\_\_  
Date

\_\_\_\_\_  
Premarket Notification 510 (k) Number



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JUN - 7 2000

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Arthur Eilinsfeld  
Director of Regulatory Affairs  
Fresenius Medical Care North America  
Dialysis Products Division  
Two Ledgemont Center  
95 Hayden Avenue  
Lexington, MA 02420

Re: K000702  
Combilines™ Hemodialysis Blood Tubing Set  
Transducer Protectors  
Dated: May 23, 2000  
Received: May 25, 2000  
Regulatory Class: II  
21 CFR §876.5820/Procode: 78 FIB and FJK

Dear Mr. Eilinsfeld:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Daniel G. Schultz, M.D.  
Captain, USPHS  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure(s)

**510(k) Premarket Notification  
Combilines™ Hemodialysis Blood Tubing Set  
Transducer Protector**

---

**Indications for Use Statement**

**Device Name:**

Combilines™ Hemodialysis Blood Tubing Set Transducer Protectors

**Indications for Use:**

The Fresenius Combilines™ Hemodialysis Blood Tubing Set Transducer Protectors are single use, disposable, prescription devices intended for use as protective devices for pressure monitors on hemodialysis machines, as well as to help protect the sterility of the blood tubing fluid pathway. The filter helps prevent cross-contamination by viruses, bacteria, and other particulate matter while preventing the flow of fluids to the hemodialysis machine's pressure transducer.

Please Do Not Write Below This Line – Continue On Another Page If Needed


---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

  
(Division Sign-Off)  
Division of Reproductive, Abdominal, ENT,  
and Radiological Devices  
510(k) Number 45000702

**Fresenius Medical Care North America**

Corporate Headquarters: Two Ledgesmont Center 95 Hayden Avenue Lexington, MA 02420 (781) 402-9000

PAGE 26